沪指，年内收盘新高！

Group 1: Market Overview - The A-share market saw an increase with the Shanghai Composite Index rising by 0.5%, Shenzhen Component Index up by 0.37%, and the ChiNext Index increasing by 0.34% as of the close on July 18 [1] - The total trading volume in the A-share market reached 1.59 trillion yuan, showing an increase compared to the previous day [1] - In the Hong Kong market, the Hang Seng Index and Hang Seng Tech Index both rose by over 1%, driven by the performance of heavyweight stocks [1] Group 2: Rare Earth Permanent Magnet Sector - The rare earth permanent magnet sector experienced a strong performance on July 18, with stocks like China Northern Rare Earth Group and Baotou Steel rising significantly [2] - A new rare earth mineral named "Huanghoite-(Nd)" was recently approved, discovered by a research team from China University of Geosciences, highlighting the ongoing exploration and resource diversity in the Bayan Obo mine [2][3] - The discovery of Huanghoite further emphasizes the complexity and resource diversity of the Bayan Obo mine, which is the largest rare earth deposit in the world [3] Group 3: Lithium Sector - The lithium sector saw significant gains, with stocks like Jinyuan Co. and Shengxin Lithium Energy hitting the daily limit [4] - Lithium carbonate futures prices have rebounded sharply, rising from around 58,000 yuan to approximately 70,980 yuan, marking an increase of over 20% since late June [4] - Recent regulatory actions regarding lithium resource development have been noted, including a requirement for certain lithium mines to complete resource verification reports by September 30 [4] Group 4: Innovative Drug Sector - The innovative drug sector has been active, with stocks like Angli Kang hitting the daily limit and reaching new historical highs [5] - The Hong Kong innovative drug sector also saw significant increases, with companies like Lepu Biopharma and Akeso rising by over 20% and 10% respectively [5] - The National Healthcare Security Administration announced a new dual-track system for drug insurance, which aims to integrate high-value innovative drugs into commercial insurance to alleviate pressure on basic medical insurance funds [6]